Xenon Pharmaceuticals Inc. (XENE)

NASDAQ: XENE · USD

$36.4

+0.37 (+1.0%)· Recorded snapshot

Market cap	3.5B
Net income (ttm)	-409.2M
EPS (ttm)	-$4.73
Shares out	96.8M
Volume	1,761,777
Beta	0.60

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -409.2M
EPS (ttm): -$4.73
Market cap: 3.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-43.6

P25 n/aP50 n/aP75 n/a

ROIC-29.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All XENE indicators

Market & fundamental data

Available fields

185

Groups with data

Currency

USD

Showing 185 of 185 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001582313
Company name	Xenon Pharmaceuticals Inc.
Country	Canada
Country code	US
CUSIP number	98420N105
Earnings date	2026-11-10
Earnings time	amc
Employees	370
Employees change	43
Employees growth	13.15%
Enterprise value	$2.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1996
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2014-11-05
Is primary listing	Yes
Is SPAC	No
ISIN number	CA98420N1050
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.5B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$36.38
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	XENE
Website	https://www.xenon-pharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-12.99%
FCF / EV yield	-14.97%
FCF yield	-9.67%
Forward EV/Sales	2,688.85x
Forward P/S	4,161.84x
P/B ratio	2.8x
Price / tangible book value	2.82x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.1M
ROA	-28.02%
ROA (5Y)	-18.62%
ROCE	-35.31%
ROE	-43.62%
ROE (5Y)	-28.66%
ROIC	-29.18%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1M
Depreciation and amortization	$2.4M
EBIT	$-441.6M
EBITDA	$-439.2M
EPS	$-4.73
FCF per share	$-3.50
Financing cash flow	$958.9M
Free cash flow	$-338.5M
Free cash flow minus SBC	$-400M
Gross profit	$-352.5M
Income taxes	$-1.9M
Investing cash flow	$-637.3M
Net cash flow	$-15.9M
Net income	$-409.2M
Operating cash flow minus SBC	$-399M
Operating income	$-441.6M
Stock-based compensation	$61.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	40.57
Book value per share	$12.84
Debt / equity	0.01
Long-term assets	$349.9M
Long-term liabilities	$8.4M
Net cash (debt)	$1.2B
Net cash / market cap	35.39%
Net cash growth	101.04%
Net debt / equity	-1
Piotroski F-Score	2
Property, plant and equipment	$13.2M
Shareholders' equity	$1.2B
Tangible book value	$1.2B
Tangible book value per share	$12.84
Total assets	$1.3B
Total cash	$930.7M
Total debt	$6.4M
Total liabilities	$53.4M
WACC	7.56%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$945.9M
Current liabilities	$45M
Current ratio	21.02
Net working capital	$-28.5M
Quick ratio	20.71
Working capital	$900.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-10.31%
Dividend yield	0%
Shareholder yield	-10.31%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	336.89%
10Y return CAGR	15.89%
10Y total return	336.89%
150-day SMA	$54.58
1D price change	1.03%
1M price change	-1.25%
1M total return	-1.25%
1W price change	0.58%
1W total return	0.58%
1Y price change	-12.91%
1Y return CAGR	-12.92%
1Y total return	-12.91%
20-day SMA	$35.97
200-day SMA	$52.40
3M price change	-44.54%
3M total return	-44.54%
3Y price change	18.17%
3Y return CAGR	5.72%
3Y total return	18.17%
50-day SMA	$46.29
50-day SMA vs 200-day SMA	50under200
52-week high	$72.66
52-week high date	2026-07-09
52-week low	$33.38
52-week low date	2026-10-16
5Y price change	21.24%
5Y return CAGR	3.93%
5Y total return	21.24%
6M price change	-32.77%
6M total return	-32.77%
All-time high	$72.66
All-time high date	2026-07-09
All-time low	$2.10
All-time low date	2017-11-16
Average true range (ATR)	$1.50
Average volume	1.5M
Beta (1Y)	0.39
Beta (2Y)	0.76
Beta (5Y)	0.6
Change from 52-week high	-49.93%
Change from 52-week low	8.99%
Change from all-time high	-49.79%
Change from all-time low	1,637.14%
Change from open	1.73%
Day's gap	-0.69%
Dollar volume	$64.1M
High price	$36.61
Low price	$35.56
Monthly RSI	43.06
Open price	$35.76
Position in 52-week range	78.1%
Premarket change	-0.36%
Premarket close	$36.01
Premarket price	$35.88
Premarket volume	2K
Previous close	$36.01
Price vs 150-day SMA	-33.17%
Price vs 20-day SMA	1.41%
Price vs 200-day SMA	-30.38%
Price vs 50-day SMA	-21.2%
Relative volume	1.15
RSI	39.54
Sharpe ratio	0.05
Sharpe ratio (3Y)	0.24
Sharpe ratio (5Y)	0.24
Sortino ratio	0.19
Sortino ratio (3Y)	0.52
Sortino ratio (5Y)	0.49
Volume	1.8M
Weekly RSI	32.91
YTD price change	-18.61%
YTD total return	-18.61%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	90.9M
Float percentage	93.86%
Shares change (QoQ)	14.04%
Shares change (YoY)	10.31%
Shares held by insiders	0.17%
Shares held by institutions	100.98%
Shares outstanding	96.8M
Short % of float	6.65%
Short % of shares	6.24%
Short ratio	2.7 days

Deeper analysis on XENE

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this XENE report

Is a complete XENE research report available?

No complete published report is available for Xenon Pharmaceuticals Inc. (XENE) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Xenon Pharmaceuticals Inc. (XENE)

Price

Financial snapshot

Fair-value bridge

Latest news · XENE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All XENE indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on XENE

Frequently asked questions